Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
Add more filters










Publication year range
1.
Cell Host Microbe ; 15(3): 363-73, 2014 Mar 12.
Article in English | MEDLINE | ID: mdl-24629342

ABSTRACT

Herpesviruses, including human cytomegalovirus (HCMV), encode multiple microRNAs (miRNA) whose targets are just being uncovered. Moreover, miRNA function during the virus life cycle is relatively unknown. We find that HCMV miRs UL112-1, US5-1, and US5-2 target multiple components of the host secretory pathway, including VAMP3, RAB5C, RAB11A, SNAP23, and CDC42. A HCMV miR UL112-1, US5-1, and US5-2 triple mutant displayed aberrant morphogenesis of the virion assembly compartment (VAC), increased secretion of noninfectious particles, and increased IL-6 release from infected cells. Ectopic expression of miRs UL112-1, US5-1, and US5-2 or siRNAs directed against RAB5C, RAB11A, SNAP23, and CDC42 caused the loss of Golgi stacks with reorganization into structures that resemble the VAC and a decrease in cytokine release. These observations indicate that multiple HCMV miRNAs coordinately regulate reorganization of the secretory pathway to control cytokine secretion and facilitate formation of the VAC for efficient infectious virus production.


Subject(s)
Cytokines/antagonists & inhibitors , Cytomegalovirus/physiology , Host-Pathogen Interactions , MicroRNAs/genetics , MicroRNAs/metabolism , Secretory Pathway/genetics , Virus Assembly , Cytokines/metabolism , Cytomegalovirus/genetics , Golgi Apparatus/physiology , Golgi Apparatus/virology , Humans
2.
Neuron ; 81(2): 294-305, 2014 Jan 22.
Article in English | MEDLINE | ID: mdl-24389009

ABSTRACT

The orchestration of brain function requires complex gene regulatory networks that are modulated, in part, by microRNAs (miRNAs). These noncoding RNAs associate with argonaute (Ago) proteins in order to direct posttranscriptional gene suppression via base pairing with target transcripts. In order to better understand how miRNAs contribute to human-specialized brain processes and neurological phenotypes, identifying their targets is of paramount importance. Here, we address the latter by profiling Ago2:RNA interactions using HITS-CLIP to generate a transcriptome-wide map of miRNA binding sites in human brain. We uncovered ∼ 7,000 stringent Ago2 binding sites that are highly enriched for conserved sequences corresponding to abundant brain miRNAs. This interactome points to functional miRNA:target pairs across >3,000 genes and represents a valuable resource for accelerating our understanding of miRNA functions in brain. We demonstrate the utility of this map for exploring clinically relevant miRNA binding sites that may facilitate the translation of genetic studies of complex neuropsychiatric diseases into therapeutics.


Subject(s)
Binding Sites/genetics , Gyrus Cinguli/metabolism , MicroRNAs/genetics , MicroRNAs/metabolism , Motor Cortex/metabolism , Adult , Aged , Animals , Argonaute Proteins/genetics , Argonaute Proteins/metabolism , Autoradiography , Base Sequence , Gene Regulatory Networks , Humans , Immunoprecipitation , Male , Mice , Middle Aged , Motor Cortex/cytology , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/metabolism , Postmortem Changes , RNA, Messenger , Transcriptome/physiology
3.
Comp Med ; 62(5): 381-90, 2012 Oct.
Article in English | MEDLINE | ID: mdl-23114041

ABSTRACT

Standardized protocols for maintaining near-normal glycemic levels in diabetic rodent models for testing therapeutic agents to treat disease are unavailable. We developed protocols for 2 common models of spontaneous type 1 diabetes, the BioBreeding diabetes-prone (BBDP) rat and nonobese diabetic (NOD) mouse. Insulin formulation, dose level, timing of dose administration, and delivery method were examined and adjusted so that glycemic levels remained within a normal range and fluctuation throughout feeding and resting cycles was minimized. Protamine zinc formulations provided the longest activity, regardless of the source of insulin. Glycemic control with few fluctuations was achieved in diabetic BBDP rats through twice-daily administration of protamine zinc insulin, and results were similar regardless of whether BBDP rats were acutely or chronically diabetic at initiation of treatment. In contrast, glycemic control could not be attained in NOD mice through administration of insulin twice daily. However, glycemic control was achieved in mice through daily administration of 0.25 U insulin through osmotic pumps. Whereas twice-daily injections of protamine zinc insulin provided glycemic control with only minor fluctuations in BBDP rats, mice required continuous delivery of insulin to prevent wide glycemic excursions. Use of these standard protocols likely will aid in the testing of agents to prevent or reverse diabetes.


Subject(s)
Diabetes Mellitus, Type 1/drug therapy , Disease Models, Animal , Insulin, Isophane/administration & dosage , Insulin, Isophane/therapeutic use , Analysis of Variance , Animals , Blood Glucose/drug effects , Dose-Response Relationship, Drug , Drug Administration Schedule , Glycemic Index , Insulin, Isophane/pharmacology , Mice , Mice, Inbred NOD , Rats , Rats, Inbred BB
4.
Virology ; 425(2): 133-42, 2012 Apr 10.
Article in English | MEDLINE | ID: mdl-22305624

ABSTRACT

Human cytomegalovirus (HCMV) miRNAs are important for regulation of viral infection and evasion of host immune responses. Unfortunately, the importance of HCMV miRNAs cannot be addressed in vivo due to the species specificity of CMVs. Rhesus CMV (RhCMV) infection of rhesus macaques provides an important model system for HCMV pathogenesis due to the genetic similarity between the viruses. In this report, seventeen RhCMV miRNAs were identified using Next Generation Sequencing. In fibroblasts, RhCMV miRNAs associate with Argonaute proteins and display several patterns of expression, including an early peak in expression followed by decline and accumulation throughout infection. Additionally, RhCMV encodes an HCMV miR-US5-2 homologue that targets the 3' UTR of RhCMV US7. Finally, examination of salivary gland tissue from infected animals revealed the presence of a subset of viral miRNAs. This study highlights the importance of the RhCMV model system for evaluating the roles of CMV miRNAs during viral infection.


Subject(s)
Cytomegalovirus Infections/veterinary , Cytomegalovirus/genetics , Gene Expression Regulation, Viral , MicroRNAs/genetics , Primate Diseases/virology , RNA, Viral/genetics , Animals , Cell Line , Cytomegalovirus Infections/virology , Humans , Macaca mulatta , MicroRNAs/metabolism , RNA, Viral/metabolism
5.
J Virol ; 85(22): 11938-44, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21900172

ABSTRACT

Human cytomegalovirus (HCMV) encodes at least 14 microRNAs (miRNAs) that act posttranscriptionally to repress gene expression. Although several HCMV miRNA targets of both cellular and viral origin have been identified, our knowledge of their function remains limited. HCMV miRNA targets, as well as phenotypes associated with HCMV miRNA mutants, have been difficult to identify since the downregulation of targets by a single miRNA is often less than 2-fold. Several factors can contribute to the strength of repression, including the mechanism of translational inhibition, the degree of complementarity between the miRNA and target mRNA, the number of binding sites for one miRNA, and cooperativity or antagonism between miRNAs. To determine the effect of multiple miRNAs on one gene, we examined the repression of a viral gene, US7. Here we demonstrate that the HCMV-encoded miRNAs miR-US5-1 and miR-US5-2 function in a highly synergistic manner to regulate US7, even at very low miRNA concentrations. Regulation of US7 involves three functional miRNA binding sites: two that are completely complementary to the 3' untranslated region (3'UTR) and one that is imperfectly matched. Surprisingly, we observed equal contributions to inhibition from both complete and partially complementary sites, and repression was not completely abrogated until all three sites were mutated simultaneously. We also observed that the miRNA binding sites did not follow the spacing constraints for corepressive miRNAs observed in earlier reports. These results underscore the importance of evaluating the contribution of multiple miRNAs on gene regulation and shed new insight into miRNA:mRNA interactions.


Subject(s)
Cytomegalovirus/physiology , Gene Expression Regulation, Viral , Membrane Glycoproteins/biosynthesis , MicroRNAs/metabolism , Viral Proteins/biosynthesis , 3' Untranslated Regions , Binding Sites , Humans
6.
J Virol ; 85(1): 378-89, 2011 Jan.
Article in English | MEDLINE | ID: mdl-20980502

ABSTRACT

MicroRNAs (miRNAs) are a class of small noncoding RNAs involved in posttranscriptional regulation. miRNAs are utilized in organisms ranging from plants to higher mammals, and data have shown that DNA viruses also use this method for host and viral gene regulation. Here, we report the sequencing of the small RNAs in rat cytomegalovirus (RCMV)-infected fibroblasts and persistently infected salivary glands. We identified 24 unique miRNAs that mapped to hairpin structures found within the viral genome. While most miRNAs were detected in both samples, four were detected exclusively in the infected fibroblasts and two were specific for the infected salivary glands. The RCMV miRNAs are distributed across the viral genome on both the positive and negative strands, with clusters of miRNAs at a number of locations, including near viral genes r1 and r111. The RCMV miRNAs have a genomic positional orientation similar to that of the miRNAs described for mouse cytomegalovirus, but they do not share any substantial sequence conservation. Similar to other reported miRNAs, the RCMV miRNAs had considerable variation at their 3' and 5' ends. Interestingly, we found a number of specific examples of differential isoform usage between the fibroblast and salivary gland samples. We determined by real-time PCR that expression of the RCMV miRNA miR-r111.1-2 is highly expressed in the salivary glands and that miR-R87-1 is expressed in most tissues during the acute infection phase. Our study identified the miRNAs expressed by RCMV in vitro and in vivo and demonstrated that expression is tissue specific and associated with a stage of viral infection.


Subject(s)
Fibroblasts/virology , Herpesviridae Infections/virology , MicroRNAs/metabolism , Muromegalovirus/pathogenicity , Salivary Glands/virology , Animals , Cells, Cultured , Fibroblasts/metabolism , Heart Transplantation , Mice , MicroRNAs/genetics , Muromegalovirus/genetics , Muromegalovirus/metabolism , Organ Specificity , Rats , Salivary Glands/metabolism , Transplantation, Homologous
7.
Vaccine ; 29(5): 1090-8, 2011 Jan 29.
Article in English | MEDLINE | ID: mdl-21134447

ABSTRACT

An estimated 1 out of every 5 Americans is infected with herpes simplex virus type 2 (HSV-2). Efforts in developing a potent vaccine for HSV-2 have shown limited success. Here we describe a heterologous vaccination strategy for HSV-2 based on an intramuscular DNA prime followed by a liposome-encapsulated antigen boost delivered intranasally. Both portions of the vaccine express the immunogenic HSV-2 glycoprotein D. In female Balb/c mice, this heterologous immunisation regimen stimulated high titers of serum neutralising antibodies, a DNA priming dose dependent T helper type response, enhanced mucosal immune responses and potent protective immunity at the portal of entry for the virus: the vaginal cavity. A clear synergistic effect on immune responses and protection from infection was seen using this heterologous immunisation approach. Suboptimal DNA prime (0.5 µg) followed by the liposome boost resulted in an 80% survival rate when mice were infected 2 weeks after immunisation. A higher dose of DNA priming (5 µg) followed by the liposome boost resulted in sterilising immunity in 80% of mice. The vaccine induced durable protection in mice, demonstrated by a 60% survival rate when lethal infections were performed 20 weeks after the immunisation primed with 0.5 µg of DNA vaccine.


Subject(s)
Herpes Simplex Virus Vaccines/administration & dosage , Herpes Simplex Virus Vaccines/immunology , Herpesvirus 2, Human/immunology , Immunization, Secondary/methods , Vaccination/methods , Administration, Mucosal , Animals , Antibodies, Neutralizing/blood , Antibodies, Viral/blood , Female , Immunity, Mucosal , Injections, Intramuscular , Mice , Mice, Inbred BALB C , Survival Analysis , Time Factors , Vaccines, DNA/administration & dosage , Vaccines, DNA/immunology , Vaccines, Subunit/administration & dosage , Vaccines, Subunit/immunology , Vagina/immunology , Viral Envelope Proteins/genetics , Viral Envelope Proteins/immunology
8.
PLoS Pathog ; 6(6): e1000967, 2010 Jun 24.
Article in English | MEDLINE | ID: mdl-20585629

ABSTRACT

Global gene expression data combined with bioinformatic analysis provides strong evidence that mammalian miRNAs mediate repression of gene expression primarily through binding sites within the 3' untranslated region (UTR). Using RNA induced silencing complex immunoprecipitation (RISC-IP) techniques we have identified multiple cellular targets for a human cytomegalovirus (HCMV) miRNA, miR-US25-1. Strikingly, this miRNA binds target sites primarily within 5'UTRs, mediating significant reduction in gene expression. Intriguingly, many of the genes targeted by miR-US25-1 are associated with cell cycle control, including cyclin E2, BRCC3, EID1, MAPRE2, and CD147, suggesting that miR-US25-1 is targeting genes within a related pathway. Deletion of miR-US25-1 from HCMV results in over expression of cyclin E2 in the context of viral infection. Our studies demonstrate that a viral miRNA mediates translational repression of multiple cellular genes by targeting mRNA 5'UTRs.


Subject(s)
5' Untranslated Regions/genetics , Cell Cycle Proteins/genetics , Gene Expression Regulation , MicroRNAs/genetics , RNA, Messenger/genetics , RNA, Viral/genetics , Virus Replication/genetics , Blotting, Western , Cells, Cultured , Cyclins/antagonists & inhibitors , Cyclins/genetics , Cyclins/metabolism , Cytomegalovirus/physiology , Cytomegalovirus Infections/genetics , Cytomegalovirus Infections/virology , Down-Regulation , Humans , Kidney/cytology , Kidney/metabolism , Luciferases/metabolism , RNA-Induced Silencing Complex/genetics , Reverse Transcriptase Polymerase Chain Reaction
9.
Diabetes ; 59(1): 110-8, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19794063

ABSTRACT

OBJECTIVE: The contribution of antecedent viral infection to the development of type 1 diabetes in humans is controversial. Using a newer rat model of the disease, we sought to 1) identify viruses capable of modulating diabetes penetrance, 2) identify conditions that increase or decrease the diabetogenicity of infection, and 3) determine whether maternal immunization would prevent diabetes. RESEARCH DESIGN AND METHODS: About 2% of LEW*1WR1 rats develop spontaneous autoimmune diabetes, but disease penetrance is much higher if weanling rats are exposed to environmental perturbants including Kilham rat virus (KRV). We compared KRV with other viruses for diabetogenic activity. RESULTS: Both KRV and rat cytomegalovirus (RCMV) induced diabetes in up to 60% of LEW*1WR1 rats, whereas H-1, vaccinia, and Coxsackie B4 viruses did not. Simultaneous inoculation of KRV and RCMV induced diabetes in 100% of animals. Pretreatment of rats with an activator of innate immunity increased the diabetogenicity of KRV but not RCMV and was associated with a moderate rate of diabetes after Coxsackie B4 and vaccinia virus infection. Inoculation of LEW*1WR1 dams with both KRV and RCMV prior to pregnancy protected weanling progeny from virus-induced diabetes in a virus-specific manner. CONCLUSIONS: Exposure to viruses can affect the penetrance of autoimmune diabetes in genetically susceptible animals. The diabetogenicity of infection is virus specific and is modified by immunomodulation prior to inoculation. Maternal immunization protects weanlings from virus-induced diabetes, suggesting that modification of immune responses to infection could provide a means of preventing islet autoimmunity.


Subject(s)
Diabetes Mellitus, Type 1/prevention & control , Diabetes Mellitus, Type 1/virology , Immunization/methods , Virus Diseases/complications , Virus Diseases/immunology , Animals , Cytomegalovirus Infections/immunology , Diabetes Mellitus, Type 1/genetics , Diabetes Mellitus, Type 1/immunology , Enterovirus B, Human/immunology , Enterovirus Infections/immunology , Female , Humans , Models, Animal , Poly I-C/immunology , Pregnancy , Rats , Rats, Inbred Lew , Rats, Inbred Strains , Vaccinia virus/immunology
10.
J Immunol ; 180(9): 6159-67, 2008 May 01.
Article in English | MEDLINE | ID: mdl-18424737

ABSTRACT

A variety of DNA vaccine prime and recombinant viral boost immunization strategies have been developed to enhance immune responses in humans, but inherent limitations to these strategies exist. There is still an overwhelming need to develop safe and effective approaches that raise broad humoral and T cell-mediated immune responses systemically and on mucosal surfaces. We have developed a novel mucosal immunization regimen that precludes the use of viral vectors yet induces potent T cell responses. Using hepatitis B surface Ag (HBsAg), we observed that vaccination of BALB/c mice with an i.m. HBsAg-DNA vaccine prime followed by an intranasal boost with HBsAg protein encapsulated in biologically inert liposomes enhanced humoral and T cell immune responses, particularly on mucosal surfaces. Intranasal live virus challenge with a recombinant vaccinia virus expressing HBsAg revealed a correlation between T cell immune responses and protection of immunized mice. A shortened immunization protocol was developed that was successful in both adult and neonatal mice. These results support the conclusion that this new approach is capable of generating a Th-type-1-biased, broad spectrum immune response, specifically at mucosal surfaces. The success of this design may provide a safe and effective vaccination alternative for human use.


Subject(s)
Hepatitis B Surface Antigens/immunology , Hepatitis B Vaccines/immunology , Immunity, Mucosal/physiology , Immunization, Secondary , Th1 Cells/immunology , Vaccines, DNA/immunology , Administration, Intranasal , Animals , Animals, Newborn , Antibody Formation/drug effects , Antibody Formation/physiology , Female , Hepatitis B Surface Antigens/pharmacology , Hepatitis B Vaccines/pharmacology , Humans , Immunity, Mucosal/drug effects , Liposomes , Mice , Mice, Inbred BALB C , Vaccines, DNA/pharmacology , Vaccinia virus/immunology
11.
Diabetes ; 54(9): 2727-33, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16123363

ABSTRACT

We describe a new rat model of autoimmune diabetes that arose in a major histocompatibility complex congenic LEW rat. Spontaneous diabetes in LEW.1WR1 rats (RT1(u/u/a)) occurs with a cumulative frequency of approximately 2% at a median age of 59 days. The disease is characterized by hyperglycemia, glycosuria, ketonuria, and polyuria. Both sexes are affected, and islets of acutely diabetic rats are devoid of beta-cells, whereas alpha- and delta-cell populations are spared. The peripheral lymphoid phenotype is normal, including the fraction of ART2(+) regulatory T-cells. We tested the hypothesis that the expression of diabetes would be increased by immunological perturbation of innate or adaptive immunity. Treatment of young rats with depleting anti-ART2.1 monoclonal antibody increased the frequency of diabetes to 50%. Treatment with the toll-like receptor 3 ligand polyinosinic:polycytidylic acid increased the frequency of diabetes to 100%. All diabetic rats exhibited end-stage islets. The LEW.1WR1 rat is also susceptible to collagen-induced arthritis but is free of spontaneous thyroiditis. The LEW.1WR1 rat provides a new model for studying autoimmune diabetes and arthritis in an animal with a genetic predisposition to both disorders that can be amplified by environmental perturbation.


Subject(s)
Diabetes Mellitus/genetics , Diabetes Mellitus/physiopathology , Animals , Antibodies, Monoclonal/pharmacology , Arthritis/chemically induced , Collagen/toxicity , Disease Models, Animal , Female , Lipopolysaccharides/pharmacology , Male , Poly I-C/pharmacology , Rats , Time Factors
12.
ILAR J ; 45(3): 292-302, 2004.
Article in English | MEDLINE | ID: mdl-15229376

ABSTRACT

Congenic and inbred strains of rats offer researchers invaluable insight into the etiopathogenesis of diabetes and associated complications. The inbred Bio-Breeding Zucker diabetic rat (BBZDR)/Wor rat strain is a relatively new and emerging model of type 2 diabetes. This strain was created by classical breeding methods used to introgress the defective leptin receptor gene (Lepr(fa)) from insulin-resistant Zucker fatty rats into the inbred BBDR/Wor strain background. The diabetic male BBZDR/Wor rat is homozygous for the fatty mutation and shares the genetic background of the original BB strain. Although lean littermates are phenotypically normal, obese juvenile BBZDR/Wor rats are hyperlipidemic and hyperleptinemic, become insulin resistant, and ultimately develop hyperglycemia. Furthermore, the BBZDR/Wor rat is immune competent and does not develop autoimmunity. Similar to patients with clinical diabetes, the BBZDR/Wor rat develops complications associated with hyperglycemia. The BBZDR/Wor rat is a model system that fully encompasses the ability to study the complications that affect human type 2 diabetic patients. In this review, recent work that has evaluated type 2 diabetic complications in BBZDR/Wor rats is discussed, including the authors' preliminary unpublished studies on cardiovascular disease.


Subject(s)
Diabetes Complications , Diabetes Mellitus, Type 2/complications , Disease Models, Animal , Animals , Diabetes Complications/genetics , Diabetes Complications/pathology , Diabetes Mellitus, Type 2/genetics , Rats , Rats, Inbred BB , Rats, Mutant Strains , Rats, Zucker
13.
J Biol Chem ; 279(24): 25838-48, 2004 Jun 11.
Article in English | MEDLINE | ID: mdl-15070899

ABSTRACT

Variola, the causative agent of smallpox, is a highly infectious double-stranded DNA virus of the orthopox genus that replicates within the cytoplasm of infected cells. For unknown reasons prominent skin manifestations, including "pox," mark the course of this systemic human disease. Here we characterized smallpox growth factor (SPGF), a protein containing an epidermal growth factor (EGF)-like domain that is conserved among orthopox viral genomes, and investigated its possible mechanistic link. We show that after recombinant expression, refolding, and purification, the EGF domain of SPGF binds exclusively to the broadly expressed cellular receptor, erb-B1 (EGF receptor), with subnanomolar affinity, stimulating the growth of primary human keratinocytes and fibroblasts. High affinity monoclonal antibodies specific for SPGF reveal in vivo immunoprotection in a murine vaccinia pneumonia model by a mechanism distinct from viral neutralization. These findings suggest that blockade of pathogenic factor actions, in general, may be advantageous to the infected host.


Subject(s)
Antibodies, Monoclonal/immunology , Growth Substances/physiology , Variola virus/chemistry , Viral Proteins/physiology , Amino Acid Sequence , Antibody Specificity , Cells, Cultured , Conserved Sequence , Epidermal Growth Factor/metabolism , ErbB Receptors/metabolism , Growth Substances/analysis , Growth Substances/chemistry , Humans , Intercellular Signaling Peptides and Proteins , Interferon-gamma/biosynthesis , Molecular Sequence Data , Peptides/metabolism , Viral Proteins/analysis , Viral Proteins/chemistry
14.
J Virol ; 76(13): 6832-5, 2002 Jul.
Article in English | MEDLINE | ID: mdl-12050396

ABSTRACT

Human cytomegalovirus US8 is a type I membrane protein that partially colocalizes with cellular endosomal and lysosomal proteins. Although US8 does not have discernible effects on the processing and cell surface distribution of major histocompatibility complex (MHC) class I products, we have demonstrated that US8 binds to MHC class I heavy chains in the endoplasmic reticulum.


Subject(s)
Cytomegalovirus/metabolism , Endoplasmic Reticulum/metabolism , Histocompatibility Antigens Class I/metabolism , Membrane Glycoproteins/metabolism , Viral Proteins/metabolism , Cells, Cultured , Fibroblasts , Histocompatibility Antigens Class I/chemistry , Humans , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...